DelveInsight’s, “Advanced Merkel cell carcinoma Pipeline Insight, 2023,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Advanced Merkel cell carcinoma pipeline landscape. It covers the Advanced Merkel cell carcinoma pipeline drug profiles, including Advanced Merkel cell carcinoma clinical trials and nonclinical stage products. It also covers the Advanced Merkel cell carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the Advanced Merkel cell carcinoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Advanced Merkel cell carcinoma clinical trials studies, Advanced Merkel cell carcinoma NDA approvals (if any), and product development activities comprising the technology, Advanced Merkel cell carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Key takeaways from the Advanced Merkel cell carcinoma Pipeline Report

 

• Over 20+ Advanced Merkel cell carcinoma companies are evaluating 20+ Advanced Merkel cell carcinoma pipeline therapies in various stages of development, and their anticipated acceptance in the HER2- Advanced Merkel cell carcinoma market would significantly increase market revenue.

 

• The leading Advanced Merkel cell carcinoma Companies includes Xencor, Inc., Incyte Corporation, Millennium Pharmaceuticals, Inc., Exelixis, Bristol-Myers Squibb, bluebird bio, Affini-T Therapeutics, ImaginAb, Inc., BioInvent International AB, Ocellaris Pharma, Inc., Sotio a.s., Morphogenesis, Inc., Checkpoint Therapeutics, Inc., and others.

 

• Promising Advanced Merkel Cell Carcinoma Pipeline Therapies includes XmAb18087, Pembrolizumab (MK-3475), FT500, Nivolumab, INCAGN02390, Etrumadenant, Zimberelimab, INCAGN02385, temsirolimus, vinorelbine ditartrate, INCAGN01949, Nivolumab, Ipilimumab, ABBV-181, and others.

 

• The Advanced Merkel cell carcinoma companies and academics are working to assess challenges and seek opportunities that could influence Advanced Merkel cell carcinoma R&D. The Advanced Merkel cell carcinoma pipeline therapies under development are focused on novel approaches to treat/improve Advanced Merkel cell carcinoma.

 

To explore more information on the latest breakthroughs in the Advanced Merkel cell carcinoma Pipeline treatment landscape of the report, click here @ Advanced Merkel cell carcinoma Pipeline Outlook

 

Advanced Merkel cell carcinoma Overview

 

Advanced Merkel cell carcinoma (MCC) is a very aggressive, rare neuroendocrine tumor of the skin with a high frequency of locoregional recurrence and metastasis, and a high mortality rate. Surgical resection, sentinel lymph node biopsy, and radiotherapy represent the gold standard of treatment in patients with localized disease, while chemotherapy has a significant role in the treatment of advanced disease. However, no definitive evidence on the survival impact of radiotherapy in the advanced stages has been provided to date, and response to chemotherapy remains brief in the majority of cases, indicating an urgent need for alternative approaches. Biological and genome sequencing studies have implicated multiple molecular pathways in MCC, thus leading to the development of new agents that target angiogenic factors, anti-apoptosis molecules, poly-ADP ribose polymerase, intracellular signal proteins such as the PI3K/AKT/mTOR pathway, and peptide receptors such as somatostatin receptors.

 

Latest Breakthroughs/News of Advanced Merkel cell carcinoma Treatment Landscape

 

 

• The approval is based on Data from the key Phase 3 KEYNOTE-091 trial, also known as EORTC-1416-LCG/ETOP-8-15 – PEARLS, served as the foundation for the approval. Disease-free survival, as determined by the investigator, was the primary effectiveness outcome measure (DFS). KEYTRUDA decreased the risk of disease recurrence or mortality by 27% in patients who underwent adjuvant platinum-based chemotherapy after surgical resection, regardless of PD-L1 expression (hazard ratio [HR]=0.73 [95% CI, 0.60-0.89]). The median DFS was nearly five years (58.7 months) for the KEYTRUDA arm and nearly three years (34.9 months) for the placebo arm in patients who underwent surgical resection and received adjuvant platinum-based chemotherapy, regardless of PD-L1 expression. This translates to a nearly two-year (23.8 months) DFS improvement over placebo. Of the 167 patients (14%) who did not receive adjuvant treatment, an exploratory subgroup analysis was conducted.

 

• Endometrial cancer has a robust clinical development programme at Merck. For the treatment of patients with advanced endometrial carcinoma who are pMMR, as determined by an FDA-approved test, or who are not microsatellite instability-high (MSI-H), who have disease progression after prior systemic therapy in any setting, and who are not candidates for curative surgery or radiation, Keytruda has two approved indications in the United States: in combination with LENVIMA® (lenvatinib), in collaboration with Eisai; and as a single agent.

 

• In 2016, Exelixis granted Ipsen Pharma SAS exclusive rights for the commercialization and further clinical development of cabozantinib outside of the U.S. and Japan. In 2017, Exelixis granted exclusive rights to Takeda Pharmaceutical Company Limited for the commercialization and further clinical development of cabozantinib for all future indications in Japan. Exelixis holds the exclusive rights to develop and commercialize cabozantinib in the U.S.Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Advanced Merkel cell carcinoma.

 

 

For further information, refer to the detailed Advanced Merkel cell carcinoma Unmet Needs, Advanced Merkel cell carcinoma Market Drivers, and Advanced Merkel cell carcinoma Market Barriers, click here for Advanced Merkel cell carcinoma Ongoing Clinical Trial Analysis

 

Advanced Merkel cell carcinoma Emerging Drugs Profile

 

Tidutamab: Xencor, Inc.

Tidutamab (previously XmAb18087) is a bispecific antibody that engages the immune system against tumors by binding to somatostatin receptor 2 (SSTR2) and CD3. Xencor’s XmAb® Bispecific Fc Domain serves as the scaffold for these two antigen binding domains and confers long circulating half-life, stability and ease of manufacture on tidutamab. Engagement of CD3 by tidutamab activates T cells for highly potent and targeted killing of SSTR2-expressing tumor cells.

 

Cabozantinib: Exelixis

In the U.S., CABOMETYX tablets are approved for the treatment of patients with advanced renal cell carcinoma (RCC); for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib; for patients with advanced RCC as a first-line treatment in combination with nivolumab; and for adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior vascular endothelial growth factor receptor (VEGFR)-targeted therapy and who are radioactive iodine-refractory or ineligible. CABOMETYX tablets have also received regulatory approvals in the European Union and additional countries and regions worldwide.

 

Advanced Merkel cell carcinoma Pipeline Therapeutics Assessment

There are approx. 20+ key companies which are developing the therapies for Advanced Merkel cell carcinoma. The companies which have their Advanced Merkel cell carcinoma drug candidates in the most advanced stage, i.e. phase II include, Exelixis.

 

Request a sample and discover the recent advances in Advanced Merkel cell carcinoma Ongoing Clinical Trial Analysis and Medications, click here @ Advanced Merkel cell carcinoma Treatment Landscape

 

Scope of the Advanced Merkel cell carcinoma Pipeline Report 

• Coverage- Global
• Advanced Merkel cell carcinoma Companies- Xencor, Inc., Incyte Corporation, Millennium Pharmaceuticals, Inc., Exelixis, Bristol-Myers Squibb, bluebird bio, Affini-T Therapeutics, ImaginAb, Inc., BioInvent International AB, Ocellaris Pharma, Inc., Sotio a.s., Morphogenesis, Inc., Checkpoint Therapeutics, Inc., and others.
• Advanced Merkel cell Carcinoma Pipeline Therapies- XmAb18087, Pembrolizumab (MK-3475), FT500, Nivolumab, INCAGN02390, Etrumadenant, Zimberelimab, INCAGN02385, temsirolimus, vinorelbine ditartrate, INCAGN01949, Nivolumab, Ipilimumab, ABBV-181, and others.
• Advanced Merkel Cell Carcinoma Pipeline Segmentation: Phases, Mechanism of Action, Route of Administration, Product Type

 

Dive deep into rich insights for drugs for Advanced Merkel cell carcinoma Market Drivers and Advanced Merkel cell carcinoma Market Barriers, click here @ Advanced Merkel cell carcinoma Unmet Needs and Analyst Views

 

Table of Content

1. Introduction
2. Executive Summary
3. Advanced Merkel cell carcinoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Advanced Merkel cell carcinoma – DelveInsight’s Analytical Perspective
7. Mid Stage Products (Phase II)
8. Cabozantinib: Exelixis
9. Drug profiles in the detailed report…..
10. Early Stage Products (Phase I)
11. IFx-Hu2.0: Morphogenesis
12. Drug profiles in the detailed report…..
13. Inactive Products
14. Advanced Merkel cell carcinoma Key Companies
15. Advanced Merkel cell carcinoma Key Products
16. Advanced Merkel cell carcinoma- Unmet Needs
17. Advanced Merkel cell carcinoma- Market Drivers and Barriers
18. Advanced Merkel cell carcinoma- Future Perspectives and Conclusion
19. Advanced Merkel cell carcinoma Analyst Views
20. Advanced Merkel cell carcinoma Key Companies
21. Appendix

 

Got Queries? Find out the related information on Advanced Merkel cell carcinoma Mergers and acquisitions, Advanced Merkel cell carcinoma Licensing Activities @ Advanced Merkel cell carcinoma Emerging Drugs, and Recent Trends

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services